OBJECTIVE:To probe into the efficacy of edaravone injection in treatment of acute cerebral infarction (ACI). METHODS:66 patients with ACI admitted into Jiangxi Xin'gan County People's Hospital from Jun. 2017 to Jul. 2018 were selected and divided into observation group and control group via random number table, with 33 cases in each. The control group was given conventional therapy, while the observation group was given edaravone injection based on the control group. Differences in clinical efficacy, interleukin-6 (IL-6), interleukin-13 (IL-13), endothelin-1 (ET-1), malondialdehyde (MDA) and superoxide dismutase (SOD) levels between two groups were compared. RESULTS:The total effective rate of observation group was 87.88％ (29/33), which was significantly higher than that of the control group (63.64％, 21/33), with statistically significant difference (P＜0.05); after treatment, the IL-6, IL-13, ET-1, MDA and SOD levels of observation group were significantly better than those of control group, with statistically significant differences (P＜0.05). CONCLUSIONS:The efficacy of edaravone injection in treatment of ACI is remarkable.%目的:探讨依达拉奉注射液用于急性脑梗死的疗效.方法:选取2017年6月至2018年7月江西省新干县人民医院收治的急性脑梗死患者66例,以随机数字表法分为观察组和对照组,每组33例.对照组患者给予常规治疗,观察组患者在对照组的基础上加用依达拉奉注射液.比较两组患者的临床疗效、白细胞介素6(IL-6)、白细胞介素13(IL-13)、内皮素1(ET-1)、丙二醛(MDA)及超氧化物歧化酶(SOD)水平的差异.结果:观察组患者的总有效率为87.88％(29/33),明显高于对照组的63.64％(21/33),差异有统计学意义(P＜0.05);治疗后,观察组患者IL-6、IL-13、ET-1、MDA及SOD水平明显优于对照组,差异均有统计学意义(P＜0.05).结论:依达拉奉注射液治疗急性脑梗死的疗效显著.
展开▼
